Host: Thomas Oppelt, PharmD, BCPS

Guest: Raj Dasgupta, MD, FACP, FCCP, FAASM

COVID-19 is still an ongoing public health threat, and the continual emergence of concerning variants has resulted in ongoing hospitalizations. Joining us to review VEKLURY, the first and only FDA-approved treatment for COVID-19 in hospitalized patients, its antiviral mechanism of action, and efficacy and safety results from the ACTT-1 clinical trial, is frontline COVID-19 treater Dr Raj Dasgupta.

Dr Raj Dasgupta is a quadruple board-certified pulmonary and critical care specialist at one of the largest hospitals in Los Angeles, California. He will be joined by Tom Oppelt, Senior Director of Medical Affairs at Gilead Sciences.